Brought to you by 
Horizon Pharma nets $386.5mm in convertible debt offering
18 Mar 2015
Executive Summary
Horizon Pharma PLC (markets products for arthritis, inflammation, and orphan diseases), via its Horizon Pharma Investment Ltd. subsidiary, netted from qualified institutional investors $386.5mm by selling seven-year 2.50% exchangeable unsecured senior notes (including full exercise of the $50mm overallotment). The company originally planned to sell $300mm in notes.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Horizon Pharma nets $386.5mm in convertible debt offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice